Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Gossamer Bio Inc (Gossamer) is a clinical-stage biopharmaceutical company. It develops and commercializes seralutinib (GB002) inhaled platelet-derived growth factor receptor (PDGFR), CSF1R, c-KIT inhibitor that targets pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company works with biotechnology pharmaceutical companies and academic centers, among others. It operates through its subsidiaries in Delawarethe US and Ireland, the UK. Gossamer is headquartered in San Diego, California, the US.
Headquarters
United States of America
Address
3115 Merryfield Row, Suite 120, San Diego, California, 92121
Website
www.gossamerbio.com
Telephone
1 858 6841300
No of Employees
144
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GOSS (NASD)
Revenue (2024)
$114.7M
EPS
XYZ
Net Income (2024)
XYZ
68.6%
(2024 vs 2023)
Market Cap*
$76.8M
Net Profit Margin (2024)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Gossamer Bio Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Seralutinib (GB002): |
| Pulmonary Arterial Hypertension |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In September, the company signed an option agreement to acquire Respira Therapeutics and its lead product candidate, RT234. |
| 2024 | Contracts/Agreements | In May, the company entered into an agreement with Chiesi Farmaceutici S.p.A to develop and commercialize seralutinib for the treatment of pulmonary hypertension. |
| 2020 | Contracts/Agreements | In February, the company partnered with IMIDomics to advance the discovery and development of novel treatments to address patients with IMIDs. |
Competitor Comparison
| Key Parameters | Gossamer Bio Inc | Merck & Co Inc | Pfizer Inc | Bayer AG | Gilead Sciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Germany | United States of America |
| City | San Diego | Rahway | New York City | Leverkusen | Foster City |
| State/Province | California | New Jersey | New York | Nordrhein-Westfalen | California |
| No. of Employees | 144 | 73,000 | 81,000 | 92,815 | 17,600 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Faheem Hasnain | President; Chairman; Chief Executive Officer | Executive Board | 2020 | 66 |
| Bryan Giraudo | Chief Operating Officer; Chief Financial Officer | Senior Management | 2021 | 50 |
| Richard Aranda, M.D. | Chief Medical Officer | Senior Management | 2021 | 65 |
| Jeff Boerneke | Secretary; General Counsel | Senior Management | 2021 | - |
| Rob Roscigno, Ph.D. | Senior Vice President - Clinical Development, Pulmonary Vascular Disease | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer